Beam Therapeutics (BEAM) Stock Forecast & Price Target

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$24.31

0.00 (0.00%)

(As of 04/18/2024 ET)

Beam Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$41.00
68.65% Upside

High Forecast	$57.00
Average Forecast	$41.00
Low Forecast	$20.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	7 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	8 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$41.00	$39.18	$44.27	$72.40
Predicted Upside	68.65% Upside	24.31% Upside	55.63% Upside	59.75% Upside

Get Beam Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

BEAM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BEAM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Beam Therapeutics Stock vs. The Competition

Type	Beam Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.68	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	68.65% Upside	927.96% Upside	12.32% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$57.00	+68.29%
2/28/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $42.00	-6.50%
2/28/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$27.00 ➝ $35.00	-20.87%
2/27/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$48.00 ➝ $57.00	+26.47%
1/29/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Overweight	$38.00 ➝ $40.00	+64.68%
12/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$35.00	+17.49%
12/8/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$75.00 ➝ $30.00	+4.35%
10/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/20/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/20/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
10/20/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$75.00 ➝ $20.00	+8.93%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$46.00 ➝ $47.00	+80.01%
8/9/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$60.00 ➝ $56.00	+113.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:24 AM ET.

BEAM Price Target - Frequently Asked Questions

What is Beam Therapeutics's consensus rating and price target?: According to the issued ratings of 13 analysts in the last year, the consensus rating for Beam Therapeutics stock is Hold based on the current 8 hold ratings and 5 buy ratings for BEAM. The average twelve-month price prediction for Beam Therapeutics is $41.00 with a high price target of $57.00 and a low price target of $20.00. Learn more on BEAM's analyst rating history.
Do Wall Street analysts like Beam Therapeutics more than its competitors?: Analysts like Beam Therapeutics less than other Medical companies. The consensus rating for Beam Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how BEAM compares to other companies.
Is Beam Therapeutics being upgraded by Wall Street analysts?: Over the previous 90 days, Beam Therapeutics's stock had 1 upgrade by analysts.

Does Beam Therapeutics's stock price have much upside?: According to analysts, Beam Therapeutics's stock has a predicted upside of 29.44% based on their 12-month stock forecasts.
What analysts cover Beam Therapeutics?: Beam Therapeutics has been rated by Barclays, BMO Capital Markets, JPMorgan Chase & Co., Royal Bank of Canada, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:BEAM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Beam Therapeutics (BEAM) Stock Forecast & Price Target

Beam Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

BEAM Analyst Ratings By Month

BEAM Price Targets by Month

Beam Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

BEAM Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info